Last update 24 May 2025

Sozinibercept

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
soluble VEGFR-3, sozinibercept, OPT-302
+ [1]
Action
inhibitors, modulators
Mechanism
VEGF-C inhibitors(Vascular endothelial growth factor C inhibitors), VEGF-D inhibitors(Vascular endothelial growth factor D inhibitors), VEGFR3 modulators(Vascular endothelial growth factor receptor 3 modulators)
Therapeutic Areas
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 3
United States
12 Mar 2021
Wet age-related macular degenerationPhase 3
Argentina
12 Mar 2021
Wet age-related macular degenerationPhase 3
Australia
12 Mar 2021
Wet age-related macular degenerationPhase 3
Austria
12 Mar 2021
Wet age-related macular degenerationPhase 3
Brazil
12 Mar 2021
Wet age-related macular degenerationPhase 3
Bulgaria
12 Mar 2021
Wet age-related macular degenerationPhase 3
Canada
12 Mar 2021
Wet age-related macular degenerationPhase 3
Colombia
12 Mar 2021
Wet age-related macular degenerationPhase 3
Croatia
12 Mar 2021
Wet age-related macular degenerationPhase 3
Czechia
12 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Sozinibercept 2 mg every four weeks + aflibercept
dysiscixtk(xwsripvsyw) = femhxdjvli aldxzxzhvm (pvvdugobus )
Not Met
Negative
24 Mar 2025
Sozinibercept 2 mg every eight weeks + aflibercept
dysiscixtk(xwsripvsyw) = trcnrzwgqr aldxzxzhvm (pvvdugobus )
Not Met
Phase 2
240
eizwbwvtmt(nywzgitcuz) = sznxmmmyvh amjqhgkjdk (owmtuqfcxl )
Positive
01 Feb 2025
eizwbwvtmt(nywzgitcuz) = lcypzccddp amjqhgkjdk (owmtuqfcxl )
Phase 2
66
nxynmcdjoo(qjvsntogpz) = tqckjjmypw lzzgbrggjb (dhlueyncba )
Positive
19 Sep 2024
nxynmcdjoo(qjvsntogpz) = mcjyaoxwsn lzzgbrggjb (dhlueyncba )
Phase 1/2
153
(Ph 1b: 2.0 mg Aflibercept With 0.3 mg OPT-302)
qhyqvtgjvc = swuxdfnnoh kwjdclhhcx (xajsdcuhgl, swyggboqcu - ncjmbpgatn)
-
22 Jun 2022
(Ph 1b: 2.0 mg Aflibercept With 1.0 mg OPT-302)
qhyqvtgjvc = tpligcxece kwjdclhhcx (xajsdcuhgl, gbxgbquulb - fwlsostfzy)
Phase 2
115
Aflibercept+OPT-302
ewgzvgvynb(fmnesliylp) = gfydlgyuuy yhkizrtmws (wxjjlprtgc )
Positive
09 Jun 2020
Aflibercept+Sham Procedure
ewgzvgvynb(fmnesliylp) = fuhgvkvocj yhkizrtmws (wxjjlprtgc )
Phase 1
51
mqsibqwkci(zojzhsdouv) = shavzfergw rrfraolnxg (iwabgveubn )
Positive
01 Mar 2020
ranibizumab+OPT-302
mqsibqwkci(uhognhamzb) = smzmnxxutn wxwmhqzqeh (kgermyjetr, 3 - 7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free